Abstract
Respiratory tract vaccination has an advantage of needle-free delivery and induction of mucosal immune response in the portal of SARS-CoV-2 entry. We utilized human parainfluenza virus type 3 vector to generate constructs expressing the full spike (S) protein of SARS-CoV-2, its S1 subunit, or the receptor-binding domain, and tested them in hamsters as single-dose intranasal vaccines. The construct bearing full-length S induced high titers of neutralizing antibodies specific to S protein domains critical to the protein functions. Robust memory T cell responses in the lungs were also induced, which represent an additional barrier to infection and should be less sensitive than the antibody responses to mutations present in SARS-CoV-2 variants. Following SARS-CoV-2 challenge, animals were protected from the disease and detectable viral replication. Vaccination prevented induction of gene pathways associated with inflammation. These results indicate advantages of respiratory vaccination against COVID-19 and inform the design of mucosal SARS-CoV-2 vaccines.
【초록키워드】 neutralizing antibody, SARS-CoV-2, Inflammation, vaccination, Mutation, Vaccines, S protein, Infection, lung, SARS-CoV-2 vaccines, Protein, SARS-CoV-2 variants, viral replication, response, pathway, hamster, respiratory, Critical, intranasal, mucosal, S1 subunit, human parainfluenza virus, SARS-CoV-2 entry, domain, functions, memory T, full-length S, mucosal immune, vaccination against COVID-19, Cell, tested, detectable, the disease, generate, less, the receptor-binding domain, prevented, expressing, the antibody response, 【제목키워드】 SARS-CoV-2, Vaccine, antibody, lung, hamster, intranasal, dose, human parainfluenza virus, memory T, effective, Cell, PROTECT, induce,